An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

For years, Rep. Edith Ajello has tried to legalize physician-assisted death in Rhode Island. This year she hopes the outcome ...

The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessin | The FDA ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

Antengene’s Xpovio approved for commercialization in Indonesia: Shanghai Thursday, March 6, 2025, 12:00 Hrs [IST] Antengene Corporation Limited, a leading innovative, commercial ...

According to the agency, the 15-year-old company only presented efficacy claims for its branded medication and did not include any warnings or precautions for the tablets at a tradeshow.

The company announced that it has secured three orders valued at around ₹500 crore from Power Grid Corporation of India Ltd ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

New treatments for graft-vs.-host disease, updated dosage for HPV vaccines — and Fred Hutch announces awards for graduate students.